GB001, a selective prostaglandin D2 receptor 2 antagonist, blocks signaling in the peripheral blood of healthy subjects
G. Opiteck (San Diego, United States of America), K. Taylor Meadows (San Diego, United States of America), E. Butz (Seattle, United States of America), S. Sugden (Montreal, Canada), R. Aranda (San Diego, United States of America), H. Ortega (San Diego, United States of America)
Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Session: Clinical and laboratory pharmacology in asthma
Session type: E-poster session
Number: 1421
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Opiteck (San Diego, United States of America), K. Taylor Meadows (San Diego, United States of America), E. Butz (Seattle, United States of America), S. Sugden (Montreal, Canada), R. Aranda (San Diego, United States of America), H. Ortega (San Diego, United States of America). GB001, a selective prostaglandin D2 receptor 2 antagonist, blocks signaling in the peripheral blood of healthy subjects. 1421
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010
Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Selective versus non-selective endothelin receptor antagonists Source: Annual Congress 2005 - New treatments in pulmonary hypertension Year: 2005
Serotonin (5-hydroxytryptamine) modulates cytokine and chemokine production in lipopolysaccharide-primed human monocytes via stimulation of different 5-HT receptor subtypes Source: Annual Congress 2005 - Inflammation and remodelling in allergy and asthma Year: 2005
A common intragenic marker of cysteinyl leukotrienes receptor-1 (T927C) does not correlate with a clinical response to the receptor's antagonist but is associated with peripheral blood eosinophilia Source: Eur Respir J 2001; 18: Suppl. 33, 260s Year: 2001
Distinct effects of the endothelin receptor antagonists PD 142893 (ET-A/B), BQ 788 (ET-B) and N-Ac-Trp-ET 1 Frg. 16-21 (ET-A) on oxidative stress-induced pulmonary hypertension in isolated rabbit lungs Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001
Down-regulation of allergic reactions by stimulation of prostaglandin E receptor EP3 subtype Source: Annual Congress 2004 - Insights into asthma and COPD Year: 2004
Prostaglandin D2 and the role of the DP1, DP2 and TP receptors in the control of airway reflex events Source: Eur Respir J 2015; 45: 1108-1118 Year: 2015
The pro-apoptotic effect of cysteinyl leukotriene receptor (CysLT-R) antagonist montelukast is mediated by CysLT-Rs expression on antigen-stimulated T cells Source: Eur Respir J 2003; 22: Suppl. 45, 100s Year: 2003
Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma. Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019
Cystenyl-leukotriene receptor antagonist (LRA) inhibits respiratory burst of human neutrophils Source: Eur Respir J 2003; 22: Suppl. 45, 316s Year: 2003
In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonistSource: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007
The novel dual D2 dopamine receptor, β2 -adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001
The endocannabinoids anandamide and 2-arachidonyl-glycerol (2-AG) induce pulmonary hypertension (PH) in a CB1 receptor independent manner - role of COX-2 and EP1 receptor activation Source: Eur Respir J 2005; 26: Suppl. 49, 733s Year: 2005
An orally available, highly selective 5-hydroxytryptamine 2B (5-HT2B) receptor antagonist ameliorating pulmonary and dermal fibrosis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019
The selective CXCR2 receptor antagonist SB-656933 inhibits CXCL1-induced neutrophil CD11b expression in human whole blood Source: Eur Respir J 2004; 24: Suppl. 48, 218s Year: 2004
Liver-X-receptor agonists, but not dexamethasone, inhibit leukotriene production from human white blood cells pretreated with GM-CSF and activated with fMLP Source: Annual Congress 2007 - New treatments for asthma and COPD - experimental evidence Year: 2007
Elevated expression of adenosine A1 receptor in bronchial biopsy specimens from asthmatic subjects Source: Eur Respir J 2008; 31: 311-319 Year: 2008
Effects of oral SCH 527123, a CXCR2 antagonist, on acquired immunity in healthy adults Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007
Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s) Source: International Congress 2018 – Studies on the mechanisms underlying airway disease Year: 2018